Gefitinib for the first-line treatment of NSCLC patients with
EGFR mutations in exons 19 or 21: analysis of 74 patients from
Czech Republic

a 2013

Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic

SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, Miloš PEŠEK, Vítězslav KOLEK et. al.

Základní údaje

Originální název

Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic

Autoři

Vydání

15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia, 2013

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30203 Respiratory systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 5.800

Organizační jednotka

Lékařská fakulta

ISSN

UT WoS

000339624902345

Klíčová slova anglicky

NSCLC patients; EGFR mutations

Změněno: 5. 3. 2014 10:41, Soňa Böhmová

Anotace

V originále

In a group of 74 patients with advanced NSCLC and with activated mutations v/ho were treated with gefitinib in first line, the therapy was well tolerated, median progression-free survival from gefitinib treatment initiation is 8.1 months (95% CI: 6.9; 9.3) and median overall survival (OS) was not reached.

Citovat

SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, Miloš PEŠEK, Vítězslav KOLEK, Leona KOUBKOVÁ, Marcela TOMÍŠKOVÁ, Monika ŠATÁNKOVÁ, Zdenka POVOLNÁ, Helena ČOUPKOVÁ, Libor HAVEL, Milada ZEMANOVÁ, Dimka SIXTOVÁ, František SALAJKA, Michal HRNČIARIK a Markéta ČERNOVSKÁ. Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic. In 15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia. 2013. ISSN 1556-0864.

@proceedings{1136222,
   author = {Skřičková, Jana and Bortlíček, Zbyněk and Hejduk, Karel and Pešek, Miloš and Kolek, Vítězslav and Koubková, Leona and Tomíšková, Marcela and Šatánková, Monika and Povolná, Zdenka and Čoupková, Helena and Havel, Libor and Zemanová, Milada and Sixtová, Dimka and Salajka, František and Hrnčiarik, Michal and Černovská, Markéta},
   booktitle = {15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia},
   keywords = {NSCLC patients; EGFR mutations},
   language = {eng},
   title = {Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic},
   year = {2013}
}

TY  - CONF
ID  - 1136222
AU  - Skřičková, Jana - Bortlíček, Zbyněk - Hejduk, Karel - Pešek, Miloš - Kolek, Vítězslav - Koubková, Leona - Tomíšková, Marcela - Šatánková, Monika - Povolná, Zdenka - Čoupková, Helena - Havel, Libor - Zemanová, Milada - Sixtová, Dimka - Salajka, František - Hrnčiarik, Michal - Černovská, Markéta
PY  - 2013
TI  - Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic
KW  - NSCLC patients
KW  - EGFR mutations
N2  - In a group of 74 patients with advanced NSCLC and with activated mutations v/ho were treated with gefitinib in first line, the therapy was well tolerated, median progression-free survival from gefitinib treatment initiation is 8.1 months (95% CI: 6.9; 9.3) and median overall survival (OS) was not reached.
ER  -

SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, Miloš PEŠEK, Vítězslav KOLEK, Leona KOUBKOVÁ, Marcela TOMÍŠKOVÁ, Monika ŠATÁNKOVÁ, Zdenka POVOLNÁ, Helena ČOUPKOVÁ, Libor HAVEL, Milada ZEMANOVÁ, Dimka SIXTOVÁ, František SALAJKA, Michal HRNČIARIK a Markéta ČERNOVSKÁ. Gefitinib for the first-line treatment of NSCLC patients with EGFR mutations in exons 19 or 21: analysis of 74 patients from Czech Republic. In \textit{15th World Conference on Lung Cancer, October 27 - 30, 2013, Sydney, Australia}. 2013. ISSN~1556-0864.

Podrobný výpis o publikaci